Overview
Aromatase (CYP19A1) is the cytochrome P450 enzyme that catalyzes the final and rate-limiting step of estrogen biosynthesis — the conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). It is expressed in the ovaries, placenta, adipose tissue, brain, bone, and — critically — in endometriotic lesions where local estrogen production drives disease progression.
Aromatase connects the metal-microbiome axis to estrogen-dependent disease through three pathways: metalloestrogen activation, adipose tissue inflammation, and estrobolome modulation.
Metal Connections
Metalloestrogens
cadmium and nickel are classified as metalloestrogens — metals that mimic estrogen by binding estrogen receptors (ERα) and activating estrogen-responsive gene transcription WITHOUT going through aromatase [1]. This creates a paradox for aromatase inhibitor therapy:
- Aromatase inhibitors (letrozole, anastrozole) block enzymatic estrogen production but cannot block metalloestrogen activation of ER.
- Environmental cadmium/nickel exposure may therefore undermine aromatase inhibitor efficacy in breast cancer and endometriosis.
Zinc and Aromatase
- zinc modulates aromatase activity — zinc deficiency is associated with altered androgen/estrogen ratios. Dietary zinc intake inversely associated with endometriosis risk, potentially through aromatase modulation [2].
Microbiome Connection
Estrobolome Circuit
Aromatase produces estrogen → estrogen is conjugated in the liver → conjugated estrogen enters the gut via bile → gut bacterial beta glucuronidase deconjugates it → free estrogen is reabsorbed (estrobolome recirculation). Dysbiosis alters the estrobolome, disrupting this circuit:
- Increased beta-glucuronidase activity → more estrogen recirculation → estrogen excess → endometriosis/breast cancer risk [3].
- Decreased beta-glucuronidase activity → less recirculation → estrogen depletion → metabolic syndrome, osteoporosis risk.
Aromatase and the estrobolome are two halves of estrogen homeostasis — one controls production, the other controls recycling. Both must be intact for normal estrogen levels.
Adipose Aromatase and Obesity-Microbiome Axis
In obesity, adipose tissue becomes a major estrogen source via aromatase expression. The gut microbiome drives obesity-related inflammation → adipose expansion → increased aromatase → peripheral estrogen production. This explains:
- Sex differences in CRC: Higher estrogen from adipose aromatase in obese men may be protective or pathogenic depending on context [4].
- Postmenopausal breast cancer: Adipose aromatase becomes the primary estrogen source after ovarian cessation; obesity-driven microbiome inflammation amplifies this.
Disease Relevance
Endometriosis
Endometriotic lesions express aberrant aromatase — normally absent in eutopic endometrium but highly expressed in ectopic lesions, creating local estrogen production that feeds lesion growth independent of ovarian estrogen. Combined with dysbiotic estrobolome (excess beta-glucuronidase recirculating additional estrogen), this creates a dual-source estrogen excess that drives disease [5].
Breast Cancer
Aromatase inhibitors are first-line therapy for ER+ postmenopausal breast cancer. The microbiome modulates treatment response through:
- Estrobolome activity affecting circulating estrogen levels despite aromatase blockade.
- Metalloestrogen exposure bypassing aromatase inhibition entirely.
Cross-References
- estrobolome — microbial estrogen recirculation (Primitive 7)
- beta glucuronidase — the microbial enzyme controlling estrogen deconjugation
- metalloestrogens — Cd/Ni mimicking estrogen without aromatase
- cadmium — metalloestrogen bypassing aromatase
- nickel — metalloestrogen
- zinc — modulates aromatase activity
- endometriosis — aberrant aromatase in ectopic lesions
- breast cancer — aromatase inhibitor therapy
- serotonin estrogen axis — estrogen-serotonin neuroendocrine interaction
- obesity — adipose aromatase as peripheral estrogen source